CNS pipeline · person
Ann M. Cunningham, MBA
Non-executive, non-independent director of Vistagen since January 2019 who also served as the company's Chief Commercial Officer from May 2021 to November 2022. Founder and Managing Partner of i3 Strategy Partners; previously VP, Neurodegenerative Diseases and Psychiatry at Teva and senior marketing roles at Otsuka and Eli Lilly.
- 1 company
Current roles
- Vistagen Therapeutics, Inc.Non-Executive, Non-Independent Director · Board2019–present
Past roles
- Vistagen Therapeutics, Inc.Chief Commercial Officer · Executive2021–2022
Appears with
People sharing a company with Ann.
- Cynthia L. Anderson · Vistagen Therapeutics, Inc.
- Elissa Cote · Vistagen Therapeutics, Inc.
- Gerard Sanacora · Vistagen Therapeutics, Inc.
- Gordon Keller · Vistagen Therapeutics, Inc.
- Joanne Curley · Vistagen Therapeutics, Inc.
- Jon S. Saxe · Vistagen Therapeutics, Inc.
- Joshua S. Prince · Vistagen Therapeutics, Inc.
- Margaret M. FitzPatrick · Vistagen Therapeutics, Inc.
- Mark Wallace · Vistagen Therapeutics, Inc.
- Mary L. Rotunno · Vistagen Therapeutics, Inc.
- Maurizio Fava · Vistagen Therapeutics, Inc.
- Michael R. Liebowitz · Vistagen Therapeutics, Inc.
- Reid G. Adler · Vistagen Therapeutics, Inc.
- Sanjay Mathew · Vistagen Therapeutics, Inc.
- Shawn K. Singh · Vistagen Therapeutics, Inc.
- Thomas Laughren · Vistagen Therapeutics, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.